PK outcomes
hepatic impairment, cirrhosis
HEPATIC IMPAIRMENT, CIRRHOSIS
Following single and multiple oral administrations of BI 685509 in patients with mild or moderate hepatic impairment, the drug was rapidly absorbed (median tPharmacokinetic parameters of BI 685509 treatmentn-1.n-2.Abbreviations: BID, twice daily; CL/F, apparent clearance; CLPharmacokinetic outcomes of BI 685509 in plasma. (A) Plasma concentration–time profiles of BI 685509 in Child–Pugh class A and B patients and matched healthy volunteers after single-dose administration. Plasma CThe PK of multiple doses of BI 685509 were consistent with the single-dose results and between patient groups (Table A comparison of patients with hepatic impairment with matched HVs showed that exposure was ~40% and ~27% higher in patients with CP-A and CP-B cirrhosis, respectively. The CL/F and V